Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

被引：66
|
作者：
Selvan, Senthamil R. [1 ]
Dowling, John P. [2 ]
Kelly, William K. [1 ]
Lin, Jianqing [1 ]
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Immunol & Microbial Pathogenesis Grad Program, Philadelphia, PA 19107 USA
来源：
CURRENT CANCER DRUG TARGETS | 2016年 / 16卷 / 09期
关键词：
Cancer immunotherapy; combination therapy; indoleamine 2,3-dioxygenase (IDO); IDO inhibitors; immune tolerance; REGULATORY T-CELLS; NATURAL-KILLER-CELLS; PLASMACYTOID DENDRITIC CELLS; TUMOR-INFILTRATING LYMPHOCYTES; BLOOD MONONUCLEAR-CELLS; DRAINING LYMPH-NODES; SUPPRESSOR-CELLS; PERIPHERAL-BLOOD; LUNG-CANCER; TRYPTOPHAN CATABOLISM;
D O I：
10.2174/1568009615666151030102250
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
引用
收藏
页码：755 / 764
页数：10
相关论文
共 50 条
  • [1] Indoleamine 2,3-dioxygenase, Tregs and Cancer
    Munn, D. H.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (15) : 2240 - 2246
  • [2] The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy
    von Bubnoff, D.
    Bieber, T.
    ALLERGY, 2012, 67 (06) : 718 - 725
  • [3] Indoleamine 2,3-dioxygenase in tumor induced tolerance
    Liu Xiao-qian
    Wang Xin
    CHINESE MEDICAL JOURNAL, 2009, 122 (24) : 3072 - 3077
  • [4] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Fujiwara, Yu
    Kato, Shumei
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Kurzrock, Razelle
    CANCER TREATMENT REVIEWS, 2022, 110
  • [5] Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
    Liu, X.
    Newton, R. C.
    Friedman, S. M.
    Scherle, P. A.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (08) : 938 - 952
  • [6] Targeting the indoleamine 2,3-dioxygenase pathway in cancer
    Moon, Yong Wha
    Hajjar, Joud
    Hwu, Patrick
    Naing, Aung
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
  • [7] Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus
    Romani, Luigina
    Zelante, Teresa
    De Luca, Antonella
    Bozza, Silvia
    Bonifazi, Pierluigi
    Moretti, Silvia
    D'Angelo, Carmen
    Giovannini, Gloria
    Bistoni, Francesco
    Fallarino, Francesca
    Puccetti, Paolo
    MEDICAL MYCOLOGY, 2009, 47 : S154 - S161
  • [8] Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer
    Ino, Kazuhiko
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2011, 23 (01) : 13 - 18
  • [9] The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
    Brochez, Lieve
    Chevolet, Ines
    Kruse, Vibeke
    EUROPEAN JOURNAL OF CANCER, 2017, 76 : 167 - 182
  • [10] Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
    Ferns, Debbie M.
    Kema, Ido P.
    Buist, Marrije R.
    Nijman, Hans W.
    Kenter, Gemma G.
    Jordanova, Ekaterina S.
    ONCOIMMUNOLOGY, 2015, 4 (02): : 1 - 7
12345